Pneumologie 2020; 74(S 01): 63
DOI: 10.1055/s-0039-3403194
Posterbegehung (PO10) – Sektion Klinische Pneumologie
Therapiefortschritte bei Kollagenose-assoziierten ILDs & pulmonaler Hypertonie
Georg Thieme Verlag KG Stuttgart · New York

The impact of time from diagnosis at baseline on long-term outcome in the GRIPHON Study: Selexipag in pulmonary arterial hypertension (PAH)

S Gaine
1   Mater Misericordiae Hospital; National Pulmonary Hypertension Unit; Mater Misericordiae University Hospital, Dublin
,
O Sitbon
2   Hôpital Bicêtre – Univ. Paris-Sud; Service de Pneumologie
,
R Channick
3   Massachusetts General Hospital, Harvard Medical School
,
K Chin
4   Ut Southwestern Medical Center
,
L Di Scala
5   Actelion Pharmaceuticals Ltd
,
N Galie
6   Istituto DI Malattie Dellʼapparato Cardiovascolare, Università DI Bologna
,
MM Hoeper
7   Medizinische Hochschule Hannover; Zentrum für Innere Medizin; Klinik für Pneumologie
,
V McLaughlin
8   University of Michigan Health System Division of Cardiovascular Medicine
,
R Preiss
5   Actelion Pharmaceuticals Ltd
,
L Rubin
9   Division of Pulmonary and Critical Care Medicine University of California; San Diego Medical School
,
G Simonneau
10   Hôpital Universitaire de Bicêtre, Université Paris-Sud
,
V Tapson
11   Cedars-Sinai Medical Center
,
HA Ghofrani
12   Universitätsklinikum Gießen und Marburg Gmbh; Standort Gießen; Med. Klinik II/V
,
I Lang
13   Medizinische Universität Wien; Akh, Wien; Klinische Abteilung für Kardiologie
› Author Affiliations
Further Information

Publication History

Publication Date:
28 February 2020 (online)

Also available at
 

Newly diagnosed PAH patients have a poor prognosis. In the randomised, event-driven, long-term GRIPHON trial, the oral IP prostacyclin receptor agonist selexipag significantly reduced the risk of morbidity/mortality events compared with placebo in PAH patients. This post-hoc analysis explores whether early initiation of selexipag, with regards to time from diagnosis, improves outcomes for PAH patients.

The treatment effect of selexipag versus placebo on the primary endpoint (composite morbidity/mortality) was evaluated for patients categorized based on their time from diagnosis at baseline using a 6-month threshold to define the newly diagnosed patients: patients treated earlier (time from diagnosis ≤ 6 months) and later (time from diagnosis > 6 months). Kaplan-Meier estimates by treatment arm and subgroup were calculated. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional-hazard models and consistency of treatment effect across subgroups was assessed using an interaction test. When patients were categorized by time from diagnosis, patients treated with selexipag earlier (time from diagnosis ≤ 6 months; N = 404) were younger and more likely to be in WHO FC II, treatment-naïve and from Asia/Eastern Europe than those treated later (time from diagnosis > 6 months; N = 752). Selexipag reduced the risk of morbidity/mortality in patients treated earlier (HR 0.45 [95% CI: 0.33 – 0.63]) and later (HR 0.70 [95% CI: 0.54 – 0.91]), with a more pronounced treatment effect in those treated earlier (interaction p-value 0.0391). Consistent results were observed in subgroup analyses by background PAH therapy.

Consistent with other studies suggesting that earlier initiation of treatment for PAH results in a more pronounced treatment effect, this analysis shows that outcome was better in patients who were treated with selexipag closer to the time of diagnosis. This pattern was observed in all background PAH therapy subgroups.